Encysive Plans Phase III Clinical Trial for PAH Drug

Drug Industry Daily
A A
Despite receiving three approvable letters from the FDA, Encysive has decided to go forward with a Phase III clinical trial of its pulmonary arterial hypertension (PAH) drug Thelin.

To View This Article:

Login

Subscribe To Drug Industry Daily